July 8, 2026

Now Available!  PTEN FDA for Prostate Carcinoma

PTEN FDA for Prostate Carcinoma is now available to support precision oncology in metastatic hormone-sensitive prostate cancer (mHSPC). This immunohistochemistry (IHC) companion diagnostic assay helps identify patients with PTEN deficiency who may benefit from a new targeted therapy, supporting biomarker-driven treatment decisions when it matters most. A quarter of advanced prostate cancer patients exhibit PTEN deficiency, an aggressive subtype linked to worse outcomes and historically limited targeted treatment options.1 Early identification of this high-risk population enables more informed, biomarker-guided therapy selection earlier in the treatment pathway. Testing is available as: A standalone PTEN FDA companion diagnostic assay As part of PanTracer™ Pro, which combines comprehensive genomic profiling (CGP) with cancer-type directed IHC testing for broad genomic insights in one streamlined solution. PTEN Laboratory Developed Test (LDT) broadening testing utility across diverse clinical scenarios. Ordering information: Rapid Turnaround Time: Global: 2 days, Tech-Only: 1 day Level of Service:  Global and Tech-Only CPT Codes*: 88360 NYS Approved: Yes   Updated test requisition forms are available here. Updates to our PTEN LDT, including a new clone and scoring algorithm, are coming soon. To support timely, accurate patient care, we will make every effort to identify prostate cancer patients and convert PTEN orders on older requisition forms to PTEN FDA for Prostate Carcinoma (CDx) when appropriate. To avoid delays and ensure clear test intent, please discontinue use of requisition forms that do not list both PTEN LDT and PTEN FDA for Prostate Carcinoma (CDx). Using the most current requisition helps ensure the correct test is ordered and processed efficiently. As a trusted leader in oncology diagnostics, NeoGenomics is committed to delivering clinically actionable diagnostics that align with evolving biomarker-driven care pathways, ensuring your reports provide the precision oncology insights that treating clinicians need at the point of care. *The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Fizazi K, Clarke NW, De Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37(1):53-68. doi:10.1016/j.annonc.2025.10.004

NeoGenomics is transitioning to a new billing system effective July 2026  

As part of this transition, invoices will be available exclusively through the NeoGenomics Client Portal, where clients can view invoices and daily charges, make payments, submit disputes or review requests, transfer internal charges, and provide any missing information. To ensure continued invoice notifications, clients should provide a designated billing email contact, including first and last name, if they have not already done so.   Notifications will include a secure link to access invoices through the Client Portal. Clients who still need to provide a designated contact may email AVClientBilling@NeoGenomics.com or call 1-866-776-5907, ext. 1513. Additional instructions and Client Portal access details will be shared closer to the transition date. For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.